A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Clinical trial NCT01815294 · COMPLETED

Trial details

NCT number: NCT01815294
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Neoplasms, Ovarian Neoplasms, Breast Advanced or Refractory Solid Malignancies

Start date: 2013-05-01
Primary completion: 2014-12-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.